Sherri's Blogs

The Inflation Reduction Act (IRA) in 2025: Impact on Pharma

As of July 2025, the Inflation Reduction Act (IRA) remains a transformative force in U.S. healthcare policy, especially for the pharmaceutical industry, even as some of its provisions and funding face adjustments or ongoing debate in Congress. Here’s an up-to-date overview of its current status and impact on pharma:

Current Status of the Inflation Reduction Act

Still Largely in Effect: Despite attempts in Congress to repeal or significantly scale back the IRA (such as H.R. 191 introduced in January 2025), most of its core prescription drug reform provisions remain operational. Recent legislation (the “One Big Beautiful Bill Act,” signed July 4, 2025) has targeted certain energy and tax credit programs for revision or rollback, but the drug pricing and Medicare negotiation components have not been fully repealed.

Active Implementation of Drug Pricing Provisions: The Centers for Medicare & Medicaid Services (CMS) continues to implement key IRA provisions, including drug price negotiations and inflation-based rebate requirements for pharma manufacturers.

Impact on Pharma in 2025

Medicare Drug Price Negotiation

Historic Shift: For the first time, the federal government can negotiate prices for a select number of high-cost drugs under Medicare. (The word “negotiate” is used loosely here.)

• Negotiation Timeline: Negotiated prices for the initial 10 Part D drugs will take effect January 2026. Additional drugs will be added annually, expanding to 20 negotiated drugs per year by 2029.
• Scope: Drugs selected are single-source brands/biosimilars with the highest Medicare spend and no generic/biosimilar competition.

Inflation Rebate Requirement

Drug manufacturers are now required to pay rebates to Medicare if they raise prices faster than inflation for drugs covered under Part B and Part D. This applies retroactively from 2023 onward and is reducing the prevalence and magnitude of annual list price increases.

Part D Benefit Redesign

• Out-of-Pocket Cap: Medicare beneficiaries see lower out-of-pocket spending thanks to an annual cap, rolling in over 2024–2025.
• Insulin and Vaccine Costs: Insulin for Medicare enrollees is capped at $35/month, and adult vaccines are now free under Part D.

Industry Impact and Adaptation

• Revenue Compression: The IRA shortens the economic lifecycle of branded drugs by imposing negotiated pricing at 9 years for small molecules and 13 years for biologics, regardless of patent life. As a result, companies are re-evaluating their launch, pricing, and R&D strategies.
• Delayed/Selective Launches: Some companies are delaying U.S. launches or being more selective about launching new drugs, particularly in rare or small indications, anticipating lower returns due to new pricing rules.
• Global “Ripple Effect”: Because U.S. drug prices often influence international reference pricing, IRA-related price reductions may also pressure prices worldwide.
• Stronger Focus on Value-Based Approaches: There’s a trend toward value-based pricing and contracts, with pharmaceutical companies increasing transparency around pricing and outcomes.

Pipeline and Investment

Early Signals: Surveyed pharma investors and executives report that the IRA is making them consider larger indications at launch, particularly for small molecules. However, concern over reduced future revenue is influencing portfolio and pipeline decisions.

Ongoing Policy and Legal Dynamics

Amendments and Challenges: Ongoing political and potential legal challenges may alter or delay some aspects of IRA’s provisions (e.g., orphan drug protections were broadened in July 2025), but the foundational drug pricing reforms remain in force at present.

Key Takeaways

• The Inflation Reduction Act’s drug price reforms are in active implementation and will reshape pharmaceutical pricing, market strategy, and patient access for years to come.
• Shorter economic lifecycles, increased pricing transparency, and government negotiation have already prompted strategic changes across the industry.
• Patients, especially Medicare beneficiaries, are benefiting from lower out-of-pocket spending, inflation-capped price increases, and the promise of lower-priced brand drugs starting in 2026.
• Pharma companies are adapting through new launch strategies, investment in value-based care, and heightened focus on market access and reimbursement planning.

What is Value-Based Care?

Value-based care is a healthcare delivery and payment model focused on improving patient outcomes and quality of care, rather than simply paying providers for the volume of services delivered. The core idea is to align provider incentives with the goal of keeping patients healthier, managing chronic conditions effectively, and delivering care that produces meaningful, measurable improvements in patients’ lives, all while controlling costs.

Key Features of Value-Based Care

• Quality Over Quantity: Providers are rewarded based on their patients’ health outcomes and the quality of care, not the number of visits, tests, or procedures performed.
• Coordinated, Patient-Centered Care: Emphasizes teamwork among health professionals to ensure care is coordinated across settings, considers the whole person (including medical and non-medical needs), and addresses an individual’s unique health goals.
• Financial Incentives for Outcomes: Payment arrangements tie reimbursement to clinical results, such as lower readmission rates, successful chronic disease management, or improved preventive care metrics.
• Proactive and Preventive Focus: Encourages early intervention and chronic disease prevention, aiming to reduce costly complications and emergency situations in the long term.
• Data-Driven Improvement: Heavy use of performance measurements, real-world evidence, and advanced analytics to guide care improvements and cost efficiencies.

Common Value-Based Care Models

• Accountable Care Organizations (ACOs): Groups of providers held collectively responsible for quality and cost outcomes of a defined patient population.
• Bundled Payments: Single set payment for all services related to a treatment, episode, or condition (e.g., knee replacement), incentivizing efficiency and coordination.
• Shared Savings and Risk Models: Providers earn bonuses if they reduce costs while meeting quality targets and may be responsible for excess spending if they do not.
• Patient-Centered Medical Homes: Team-based primary care that coordinates all aspects of patient health.

Benefits for Patients & the Healthcare System

• Better Patient Outcomes: Improved chronic disease management and prevention; fewer hospitalizations and complications.
• Lower Costs: By reducing unnecessary procedures and hospitalizations, value-based care aims to control healthcare spending.
• Improved Patient Experience: Easier navigation of the healthcare system, more time with providers, and care that aligns with personal goals.

Why It Matters

Value-based care is being adopted because the traditional “fee-for-service” system tends to incentivize more procedures and visits, regardless of quality or results. In contrast, value-based models help drive high-quality, efficient, and equitable care, focusing resources where they have the greatest real-world impact for patients and communities.

In summary: Value-based care is transforming healthcare by incentivizing quality, coordination, and outcomes over volume, resulting in healthier patients and a more sustainable healthcare system.